Get the Stockscreener App
1.83
1.10%
0.02
After Hours:
1.84
0.01
+0.55%
Palisade Bio Inc stock is traded at $1.83, with a volume of 1.81M.
It is up +1.10% in the last 24 hours and down -21.79% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.81
Open:
$1.8
24h Volume:
1.81M
Relative Volume:
0.48
Market Cap:
$318.02M
Revenue:
$250.00K
Net Income/Loss:
$-16.78M
P/E Ratio:
-1.2325
EPS:
-1.4848
Net Cash Flow:
$-10.85M
1W Performance:
+1.67%
1M Performance:
-21.79%
6M Performance:
-14.49%
1Y Performance:
+169.08%
1-Day Range:
$1.76
$1.86
1-Week Range:
$1.76
$1.98
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.83 | 314.54M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
10 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
RA Capital and partners disclose 9.99% stake in Palisade Bio (PALI) via warrants and shares - Stock Titan
[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure - Stock Titan
Commodore Capital reports 12.37M-share stake in Palisade Bio (PALI) - Stock Titan
Perceptive Advisors (NASDAQ: PALI) reports a 7.9% collective stake in Palisade Bio - Stock Titan
Ameriprise/Columbia disclose 8.71M-share stake in Palisade Bio (NASDAQ: PALI) - Stock Titan
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - Yahoo Finance
PALI Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Palisade Bio Incmay offer and sell up to $300 million of securitiesSEC filing - marketscreener.com
Palisade Bio (NASDAQ: PALI) files $300M shelf to offer securities - Stock Titan
Palisade Bio Q1 net loss widens on higher R&D costs - TradingView
Palisade Bio (PALI) ramps PALI-2108 trials with $132.6M cash runway - Stock Titan
BRIEF-Palisade Bio Q1 EPS USD -0.05 - TradingView
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewswire
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Palisade Bio Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Palisade Bio Data Supports Once-Daily Ulcerative Colitis Treatment Due to Sustained IC90 Coverage - geneonline.com
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug By Investing.com - Investing.com South Africa
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug - Investing.com
Palisade UC pill stayed above IC90 through the dosing interval - Stock Titan
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis - Yahoo Finance
MSN Money - MSN
Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI) - Stock Titan
Palisade Bio Participates in Virtual Investor "What This Means" Segment - 富途牛牛
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
PALI Palisade Bio posts narrower than expected Q4 2025 loss, shares gain more than four percent.Secondary Offering - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat
Brokers Issue Forecasts for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan
Palisade Bio Develops Crohn’s Disease Treatment Following Positive Study - HarianBasis.co
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Insider Monkey
Palisade Bio to present ulcerative colitis data at DDW conference By Investing.com - Investing.com India
Palisade Bio to present ulcerative colitis data at DDW conference - Investing.com
Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative Colitis - Quiver Quantitative
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewswire
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com South Africa
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):